Harrison Global Holdings Partners with Biotree to Expand Global Reach of Metabolic Syndrome Treatment

Harrison Global Holdings has signed a strategic partnership with Biotree Co., Ltd., a Korean firm developing the world's first natural product-based treatment for metabolic syndrome. Biotree has completed Phase 1 clinical trials in the US and Phase 2A trials in Korea, with pending Phase 2B trials. The drug is expected to be conditionally approved and launch in 2026. Harrison Global plans to pursue global expansion of Biotree's new drug technology and raw materials.

Title: Harrison Global Holdings Partners with Biotree Co., Ltd. to Expand Natural Metabolic Syndrome Treatment

Harrison Global Holdings (NASDAQ:BLMZ), a Japanese entertainment and voice actor management company, has signed a strategic partnership with Biotree Co., Ltd., a Korean biotech firm developing natural product-based treatments for metabolic syndrome. The partnership aims to expand the global reach of Biotree's lead drug candidate, PH-100, which has shown significant promise in reducing inflammatory markers without adverse effects.

Biotree's PH-100 has completed Phase 1 trials in the US and Phase 2A trials across 12 Korean hospitals, with Phase 2B trials ongoing. The drug is expected to be conditionally approved and launched in the first half of 2026, pending the successful completion of the Phase 2B trials. The partnership scope includes establishing joint ventures, developing new natural product drugs, sharing distribution channels, and supporting regulatory compliance across the US, Japan, China, and Asian markets.

The partnership represents a significant strategic pivot for Harrison Global, which is primarily focused on entertainment and voice actor management. Biotree brings strong credentials to the table, with over 50 patents, 130+ SCI papers, and multiple regulatory certifications, including FDA NDI and IND. The company's lead drug candidate, PH-100, is based on Seapolynol, a marine polyphenol extracted from Gamtae seaweed, which has shown potential in treating metabolic syndrome and related conditions.

The strategic rationale for this cross-industry partnership remains unclear, as does Harrison Global's expertise in pharmaceutical development and commercialization. While diversification can be valuable, such dramatic shifts into highly regulated industries typically require specialized knowledge and substantial capital investment, making this an unconventional and potentially risky strategic move for shareholders.

Harrison Global Holdings plans to actively pursue the global expansion of Biotree's new drug technology and raw materials for metabolic syndrome treatments, including exports to markets such as the US, Japan, China, and Asia. The company aims to contribute to human health by working closely with Biotree to support the joint development and distribution of its products.

References:
[1] https://www.stocktitan.net/news/BLMZ/harrison-global-holdings-signs-strategic-international-business-k6qfsz6q2us2.html